Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Closed Mourning Day 01-08 16:00:00 EST

0.7449

-0.0329

-4.23%

盘后0.7300

-0.0149-2.00%

19:42 EST

High0.7802	Low0.7168	Vol1.65M
Open0.7800	D1 Closing0.7778	Amplitude8.14%
Mkt Cap77.32M	Tradable Cap45.78M	Total Shares103.80M
T/O1.23M	T/O Rate2.69%	Tradable Shares61.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":0.7449,"timestamp":1736370000000,"preClose":0.7778,"halted":0,"volume":1651642,"hourTrading":{"tag":"盘后","latestPrice":0.73,"preClose":0.7449,"latestTime":"19:42 EST","volume":4937,"amount":3649.5669,"timestamp":1736383350792},"delay":0,"floatShares":61454000,"shares":103796406,"eps":-0.489086,"marketStatus":"Closed Mourning Day","change":-0.0329,"latestTime":"01-08 16:00:00 EST","open":0.78,"high":0.78015,"low":0.7168,"amount":1229780.04630334,"amplitude":0.081448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.489086,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":7,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":0.7778,"preHourTrading":{"tag":"盘前","latestPrice":0.7703,"preClose":0.7778,"latestTime":"09:28 EST","volume":152928,"amount":119292.786288,"timestamp":1736346510036},"postHourTrading":{"tag":"盘后","latestPrice":0.73,"preClose":0.7449,"latestTime":"19:42 EST","volume":4937,"amount":3649.5669,"timestamp":1736383350792},"volumeRatio":1.2341590639359248},"requestUrl":"/m/hq/s/UNCY/wiki","defaultTab":"wiki","newsList":[{"id":"2501077132","title":"Positive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2501077132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501077132?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:35","pubTimestamp":1736350531,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-buy-recommendation-for-unicycive-therapeutics-driven-by-promising-trial-results-and-revenue-forecasts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-buy-recommendation-for-unicycive-therapeutics-driven-by-promising-trial-results-and-revenue-forecasts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","UNCY"],"gpt_icon":0},{"id":"2501620834","title":"Unicycive Therapeutics announces publication of OLC dose escalation data","url":"https://stock-news.laohu8.com/highlight/detail?id=2501620834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501620834?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:12","pubTimestamp":1736251927,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) announced that data from the Company’s oxylanthanum carbonate Phase 1 dose escalation study in healthy volunteers was...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-announces-publication-of-olc-dose-escalation-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-announces-publication-of-olc-dose-escalation-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","UNCY"],"gpt_icon":0},{"id":"2501133270","title":"Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science","url":"https://stock-news.laohu8.com/highlight/detail?id=2501133270","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501133270?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:00","pubTimestamp":1736251200,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Jan.  07, 2025  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005221/0/en/Unicycive-Therapeutics-Announces-Publication-of-Positive-Oxylanthanum-Carbonate-OLC-Dose-Escalation-Data-in-Clinical-and-Translational-Science.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CMC","BK4006","LU0267386448.USD","UNCY","IE00BKVL7J92.USD","LU0882574139.USD","LU1363072403.SGD","BK4539","LU0170899867.USD","BK4139","IE00BHPRN162.USD","LU0149725797.USD","IE00B1BXHZ80.USD","LU0971096721.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2492695661","title":"Unicycive announces puvlication of OLC positive bioequivalence data","url":"https://stock-news.laohu8.com/highlight/detail?id=2492695661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492695661?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:15","pubTimestamp":1734437739,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) announced that data from the Company’s oxylanthanum carbonate, OLC, bioequivalence study in healthy volunteers was pu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-announces-puvlication-of-olc-positive-bioequivalence-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-announces-puvlication-of-olc-positive-bioequivalence-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","BK4539","BK4139"],"gpt_icon":0},{"id":"2492959885","title":"Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959885","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959885?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:00","pubTimestamp":1734436800,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Dec.  17, 2024  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998128/0/en/Unicycive-Therapeutics-Announces-Publication-of-Oxylanthanum-Carbonate-OLC-Positive-Bioequivalence-Data-in-Clinical-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","LENZ","BK4588","PD","BK4023","LU1169589451.USD","LU0170899867.USD","LC","BK4539","BK4139","LU1169590202.USD","BK4006","BK4166","LU0971096721.USD","IE00BKVL7J92.USD","LU0149725797.USD","IE00B1BXHZ80.USD","LU0882574139.USD","LU0267386448.USD","IE00BZ1G4Q59.USD","UNCY","LU1363072403.SGD","BK4585","IE00BHPRN162.USD"],"gpt_icon":0},{"id":"2486318019","title":"Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486318019","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486318019?lang=en_us&edition=fundamental","pubTime":"2024-11-28 19:57","pubTimestamp":1732795035,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Unicycive Therapeutics, Inc.'s  business as it appears the company may be on the cusp of a considerable accomplishment. Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. The US$61m market-cap company posted a loss in its most recent financial year of US$31m and a latest trailing-twelve-month loss of US$24m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which Unicycive Therapeutics will turn a profit, with the big question being “when will the company breakeven?”In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.Using a line of best fit, we calculated an average annual growth rate of 59%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.Manag","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breakeven-horizon-unicycive-therapeutics-inc-115715075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","PSQ","BK4112","BK4139","BK4539","QLD","QID",".IXIC","BK4588","BK4585","SQQQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","MNQmain","LU2210149790.SGD","NQmain","LU2095319765.USD","IE00BKPKM429.USD","UNCY"],"gpt_icon":1},{"id":"2485261147","title":"Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261147","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485261147?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:49","pubTimestamp":1732286940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 09:49 ET (14:49 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","LENZ"],"gpt_icon":0},{"id":"2485620774","title":"Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2485620774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485620774?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:00","pubTimestamp":1732190400,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Nov.  21, 2024  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985083/0/en/Unicycive-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences-Including-a-Fireside-Chat-at-the-Piper-Sandler-36th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","HCSG","UNCY","BK4137","BK4539"],"gpt_icon":0},{"id":"2483893053","title":"Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to ‘Buy’ Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483893053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483893053?lang=en_us&edition=fundamental","pubTime":"2024-11-15 00:35","pubTimestamp":1731602134,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of $2.00. Jas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strategic-market-position-and-fda-milestone-propel-unicycive-therapeutics-to-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strategic-market-position-and-fda-milestone-propel-unicycive-therapeutics-to-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","LENZ"],"gpt_icon":0},{"id":"2483799000","title":"BRIEF-Unicycive Announces Q3 2024 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483799000","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483799000?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:32","pubTimestamp":1731504752,"startTime":"0","endTime":"0","summary":"BRIEF-Unicycive Announces Q3 2024 Financial Results And Provides Business UpdateNov 13  - Unicycive Therapeutics Inc UNCY.O:UNICYCIVE ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE: QTRLY LOSS PER SHARE $0.05Q3 EARNINGS PER SHARE VIEW $-0.15 -- LSEG IBES DATASource text: nGNX5cJmcNFurther company coverage: UNCY.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUAB4LZYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","UNCY"],"gpt_icon":0},{"id":"2483041001","title":"Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483041001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483041001?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:35","pubTimestamp":1731501351,"startTime":"0","endTime":"0","summary":"“We are pleased with the tremendous progress we have made over the last several months highlighted by the acceptance of our New Drug Application fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-reports-q3-eps-13c-consensus-15c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-reports-q3-eps-13c-consensus-15c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","UNCY"],"gpt_icon":0},{"id":"2483006741","title":"Unicycive Therapeutics Q3 Income From Operations USD -6.251 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483006741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483006741?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX813FA8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","UNCY"],"gpt_icon":0},{"id":"2483747006","title":"Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483747006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483747006?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUAB4LZYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4539","BK4139"],"gpt_icon":0},{"id":"2483099040","title":"Unicycive Therapeutics Inc  Q3 Shr View $-0.15 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2483099040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483099040?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUAB4LZYT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"gpt_icon":0},{"id":"2483009314","title":"Press Release: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483009314","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483009314?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500100,"startTime":"0","endTime":"0","summary":"-- OLC New Drug Application  Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025--. -- Commercial Planning in Progress for 2025 Launch --. \"We are pleased with the tremendous progress we have made over the last several months highlighted by the acceptance of our New Drug Application for oxylanthanum carbonate  which may result in the potential approval of our first drug in 2025,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"If approved, we believe OLC's high potency and low pill burden would provide a best-in-class option for patients with chronic kidney disease  on dialysis who have hyperphosphatemia and face adherence challenges with current treatment regimens. With the NDA acceptance now behind us, we are actively preparing to commercialize OLC with the goal of bringing this innovative new treatment to market in the second half of 2025.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNI.USD.HKCC","BK4022","BK4232","UNI.USD.CC","R","UNCY"],"gpt_icon":0},{"id":"2482785481","title":"Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482785481","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482785481?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:47","pubTimestamp":1731329225,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics  said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.Unicycive shares were nearly 3% higher in premarket trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","UNCY","LENZ"],"gpt_icon":0},{"id":"2482178397","title":"Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2482178397","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482178397?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:31","pubTimestamp":1731328260,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics said the Food and Drug Administration accepted its application seeking approval of its lead drug candidate as a treatment for an electrolyte disorder related to kidney disease.Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target action date of June 28, 2025 for the application.The Los Altos, Calif., clinical-stage biotechnology company said oxylanthanum carbonate, if approved, would lower the pill burden in terms of the number and size per dose for patients with hyperphosphatemia, a condition involving too much phosphate in the blood that occurs in nearly all patients with end-stage renal disease.Unicycive said it was preparing to commercialize and launch the drug in the second half of 2025.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UNCY","BK4539"],"gpt_icon":0},{"id":"2482788135","title":"Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2482788135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482788135?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:07","pubTimestamp":1731326829,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for Oxylanthan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-announces-u-s-fda-acceptane-for-nda-for-olc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-announces-u-s-fda-acceptane-for-nda-for-olc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","UNCY","BK4539","BK4139"],"gpt_icon":0},{"id":"2482200905","title":"Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (Nda) for Oxylanthanum Carbonate (Olc) for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease on Dialysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2482200905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482200905?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAC22JCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"gpt_icon":0},{"id":"2482200476","title":"Unicycive Therapeutics Inc - Preparing for 2025 Commercial Launch of Olc","url":"https://stock-news.laohu8.com/highlight/detail?id=2482200476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482200476?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAC22JCV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":-0.0621},{"period":"1month","weight":0.026},{"period":"3month","weight":1.0761},{"period":"6month","weight":0.5052},{"period":"1year","weight":-0.2551},{"period":"ytd","weight":-0.0621}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.065072},{"month":2,"riseRate":0.666667,"avgChangeRate":0.127697},{"month":3,"riseRate":0.333333,"avgChangeRate":0.996651},{"month":4,"riseRate":0,"avgChangeRate":-0.298132},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.055066},{"month":6,"riseRate":0,"avgChangeRate":-0.179728},{"month":7,"riseRate":0,"avgChangeRate":-0.107364},{"month":8,"riseRate":0.25,"avgChangeRate":-0.144614},{"month":9,"riseRate":0.5,"avgChangeRate":0.038379},{"month":10,"riseRate":0.75,"avgChangeRate":0.041357},{"month":11,"riseRate":0.5,"avgChangeRate":-0.014685},{"month":12,"riseRate":0.5,"avgChangeRate":0.150198}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction